Financial advisory
Corporate transactions have become more complex. A successful transaction means dealing with important business and entrepreneurial issues from day one.
At the level of Genfit SA, this acquisition aims to consolidate its position in the field of acute and chronic liver failure (ACLF) through the integration of a clinically advanced asset (VS-01) with a solid scientific rationale supported by encouraging Phase 1b and preclinical data. Additionally, Genfit SA will also expand its pipeline in other liver diseases with significant unmet medical needs through other product candidates developed by Versantis AG.
Genfit SA was advised by a Mazars team composed of Baudouin Heron and Antonio Rubino for the financial part and Murielle Kammermann and Isabelle Bugnon for the tax and social part.
This website uses cookies.
Some of these cookies are necessary, while others help us analyse our traffic, serve advertising and deliver customised experiences for you.
For more information on the cookies we use, please refer to our Privacy Policy.
This website cannot function properly without these cookies.
Analytical cookies help us enhance our website by collecting information on its usage.
We use marketing cookies to increase the relevancy of our advertising campaigns.